Sunday 11 October 2026 Export all LLY data to Excel Powerpack

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,179.27 9.67 +0.83%
Market cap
$1.10T
P/E
39.6×
Fwd P/E
33.1×
Dividend yield
0.57%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
28.91 0.00 36.97 14.97 24.83 44.99 52.90 102.10 65.93 46.83
Piotroski F-Score
6 4 9 6 6 6 7 5 6 7
Altman Z-Score
3.42 2.75 3.52 3.23 3.57 5.14 6.47 6.99 7.89 8.61
P/S ratio
3.72 4.46 5.53 5.48 6.24 8.85 11.53 15.62 15.44 14.79
P/FCF ratio
18.37 18.00 25.18 29.05 27.75 38.74 56.77 216.52 116.64 86.31
Altman Z″-Score (non-manufacturers)
3.21 2.35 3.03 1.66 2.27 2.17 2.04 1.26 2.26 3.79
Beneish M-Score
(2.62) (3.04) (2.64) (2.52) (2.26) (2.47) (2.58) (2.18) (2.21) (1.91)
P/Operating CF
39.35 51.10 82.09 62.32 84.42 110.77 197.95 (1,708.65) 281.04 299.05
Dividend Safety Score
— — — — — — — — — 86
P/B ratio
5.61 7.64 10.90 45.34 26.31 27.37 30.54 49.07 48.72 36.34
Price to Tangible BV
13.73 27.25 14.03 0.00 0.00 0.00 0.00 0.00 297.63 68.31
EV/Sales
3.83 4.56 5.62 6.07 6.77 9.30 12.02 16.14 16.02 15.34
EV/EBITDA
17.09 25.49 23.47 21.81 22.51 33.33 39.67 68.98 49.20 35.32
EV/Operating CF
16.76 16.21 21.85 27.99 25.56 35.77 45.24 129.89 81.84 59.45
EV/FCF
18.92 18.39 25.56 32.13 30.09 40.75 59.19 223.69 121.06 89.46
Quick Ratio
0.98 0.91 1.11 0.68 0.85 0.80 0.63 0.52 0.58 0.78
Current Ratio
1.37 1.32 1.73 1.16 1.40 1.23 1.05 0.94 1.15 1.58
Net Debt/EBITDA
0.90 1.57 0.56 2.09 1.75 1.45 1.45 1.93 1.72 1.19
Debt/Assets
26.55% 30.34% 23.45% 39.30% 35.59% 31.44% 29.78% 28.62% 36.24% 36.33%
Debt/Equity
0.73 1.17 0.94 5.72 2.85 1.68 1.37 1.69 2.00 1.54
Asset Turnover
0.57 0.48 0.48 0.54 0.57 0.59 0.58 0.60 0.63 0.68
Operating CF/Net income
1.77 (27.51) 1.71 0.58 1.05 1.32 1.21 0.81 0.83 0.81
Capex/Depreciation
(0.64) (0.69) (0.75) (0.84) (1.05) (0.85) (1.22) (2.26) (2.86) (3.93)
ROE
19.10% (1.59%) 28.63% 122.26% 145.32% 74.52% 62.67% 48.43% 84.26% 101.16%
ROA
7.36% (0.49%) 7.27% 20.00% 14.42% 11.70% 12.71% 9.23% 14.84% 21.59%
ROIC
11.11% 7.25% 16.01% 19.80% 20.20% 19.29% 19.12% 15.37% 20.39% 27.34%
Return on Tangible Assets
22.14% (1.51%) 19.40% 84.82% 45.33% 45.07% 56.56% 46.18% 49.33% 45.79%
Average Days of Receivables
81.98 96.16 98.10 90.62 103.06 104.75 109.46 121.26 107.58 112.87
Research and Development Expense of Revenue
25.02% 25.51% 23.50% 25.07% 24.35% 24.47% 25.19% 27.29% 24.40% 20.46%
Selling, General and Administrative Expense of Revenue
30.76% 29.95% 27.80% 27.84% 24.94% 22.71% 22.57% 21.70% 19.08% 17.02%
Intangible Assets out of Total Assets
0.21 0.19 0.06 0.26 0.24 0.24 0.23 0.19 0.15 0.11
Share Based Compensation of Revenue
1.20% 1.41% 1.30% 1.40% 1.26% 1.21% 1.30% 1.84% 1.43% 0.96%
Graham Net Nets
(0.12) (0.16) (0.10) (0.19) (0.15) (0.08) (0.06) (0.05) (0.05) (0.03)
Graham Number
27.79 0.00 27.34 23.93 31.34 37.34 43.07 39.68 64.62 123.57
Earnings Yield
3.46% (0.24%) 2.70% 6.68% 4.03% 2.22% 1.89% 0.98% 1.52% 2.14%
Free Cash Flow Yield
5.44% 5.56% 3.97% 3.44% 3.60% 2.58% 1.76% 0.46% 0.86% 1.16%
Revenue per Share
20.05 18.99 20.91 23.97 27.04 31.22 31.65 37.91 50.01 72.64
Operating CF per Share
4.58 5.34 5.38 5.19 7.16 8.12 8.41 4.71 9.79 18.74
Capex per Share
(0.91) (1.02) (1.18) (1.11) (1.53) (1.44) (2.06) (3.83) (5.62) (8.74)
Free Cash Flow per Share
3.67 4.31 4.20 4.08 5.63 6.68 6.36 0.88 4.18 10.00
Cash per Share
5.71 7.64 7.21 2.62 4.06 4.31 2.45 3.25 3.63 8.10
Shareholders Equity per Share
13.30 11.09 10.61 2.90 6.42 10.09 11.95 12.07 15.85 29.57
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
13.30 11.09 10.61 2.90 6.42 10.09 11.95 12.07 15.85 29.57
Free Cash Flow
3,887.40 4,538.80 4,313.90 3,802.70 5,111.70 6,056.10 5,731.40 792.00 3,760.00 8,972.00
Working Capital
4,114.80 4,666.20 8,661.50 1,934.40 4,980.50 3,399.70 896.30 (1,566.20) 4,364.00 20,401.00
Capital Expenditures
(963.60) (1,076.80) (1,210.60) (1,033.90) (1,387.90) (1,309.80) (1,854.30) (3,448.00) (5,058.00) (7,841.00)
Net Current Asset Value
(9,624.00) (14,111.00) (12,449.70) (22,877.40) (23,345.80) (21,198.80) (20,679.90) (27,415.60) (31,703.00) (30,312.00)
EV/EBIT
24.93 45.43 34.16 27.21 27.43 41.45 48.15 85.29 55.95 38.00
Capex to Sales
0.05 0.05 0.06 0.05 0.06 0.05 0.07 0.10 0.11 0.12
Price to Operating Income
24.21 44.47 33.65 24.60 25.30 39.41 46.18 82.56 53.90 36.66
Other line items
Depreciation/Fixed assets
0.18 0.18 0.20 0.16 0.15 0.17 0.15 0.12 0.10 0.08
Cash ROIC
12.78% 13.61% 15.07% 18.48% 19.58% 21.32% 20.67% 2.47% 8.16% 12.02%
Accounts Receivable Turnover
4.80 3.98 3.89 3.94 3.94 3.76 3.42 3.43 3.66 3.90
Accounts Payable Turnover
4.25 3.22 3.58 3.61 3.64 4.46 3.68 3.13 2.89 2.57
Inventory Turnover
1.63 1.11 1.24 1.50 1.53 1.86 1.62 1.40 1.26 1.04
Average Days of Payables
86.25 115.77 94.11 108.64 106.95 83.38 106.29 133.94 140.01 177.65
Days of Inventory on Hand
227.68 365.87 241.54 246.68 264.95 193.96 237.27 297.53 329.06 453.91
Average Receivables
4,418.95 5,014.25 5,519.50 5,659.15 6,235.25 7,528.10 8,343.05 9,947.55 12,306.10 16,715.50
Average Payables
1,343.75 1,380.00 1,308.90 1,306.20 1,506.00 1,638.65 1,800.60 2,264.70 2,913.90 4,304.00
Average Inventory
3,503.85 4,010.10 3,778.20 3,144.40 3,585.50 3,933.15 4,097.85 5,041.25 6,680.90 10,666.50
Average Assets
37,187.40 41,893.45 44,444.70 41,597.25 42,959.60 47,719.55 49,147.90 56,748.05 71,360.65 95,595.50
Average Common Equity
14,335.40 12,874.20 11,288.50 6,804.10 4,262.15 7,490.00 9,965.10 10,819.55 12,567.85 20,403.50

Fold the line items

Columns are period end dates